Manhattan Research reports that the number of Health 2.0 consumers has doubled since 2007

Manhattan ResearchOver 60 million U.S. adults are Health 2.0 consumers - reporting to use health blogs, online support groups, prescription rating sites, and other health-related social media applications, according to pharmaceutical and healthcare market research company Manhattan Research's just released Cybercitizen Health™ v8.0 consumer study and strategic advisory service. The number of Health 2.0 consumers has doubled over the past year. The study also found that a consumer's condition, as opposed to just age or gender, is an important factor in his or her likeliness to engage in health-related social media.

"Social media is changing the way that consumers gather health information from the Internet. Patients and caregivers are no longer limited to static resources but are now sharing advice and treatment experiences online," said Meredith Abreu Ressi, Manhattan Research Vice President of Research, "And it's not just younger audiences connecting online - consumers with conditions such as cancer, fibromyalgia, and depression are also avid users of these types of resources. Health 2.0 is happening, and it's changing the way things are done in the healthcare industry."

Health 2.0 consumers are defined as consumers who have conducted one of the following activities in the past 12 months: read health-related blogs, message boards or participated in health-related chatrooms; contributed or posted health content online such as: writing or commenting on a health-related blog, adding or responding to a topic in a forum or group, or creating health related web pages, videos or audio content; used online patient support groups, message boards, chatrooms, or blogs.

Health 2.0 Podcast & DTC Advertising White Paper
Ressi reviews the latest Health 2.0 applications and consumer trends from the Health 2.0 Conference in San Francisco in a new Manhattan Research eHealth Trends podcast episode http://www.manhattanresearch.com/podcast

Manhattan Research also just released its latest healthcare marketing whitepaper revealing the latest trends in how consumers use technology for health and strategies for reaching target audiences through new media channels.

Download the white paper
http://www.manhattanresearch.com/research/white-papers/
catch-the-new-pharma-marketing-wave.aspx

About Cybercitizen Health™ v8.0
Cybercitizen Health™ v8.0 was fielded in Q3 2008 among 8,714 U.S. adults (ages 18+). In addition to the data, clients receive strategic deliverables including research reports, client briefings, and access to the Manhattan Research analyst team to answer specific questions. For topics and available therapeutic segmentations (80+), visit http://www.manhattanresearch.com/cch

About Manhattan Research
Manhattan Research, a Decision Resources, Inc. company, is a leading market research and advisory services firm for global pharmaceutical and healthcare companies. For more information, visit http://www.manhattanresearch.com.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.DecisionResourcesInc.com.

Most Popular Now

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...

Pfizer expands 'An Accord for a Healthier World' p…

Pfizer Inc. (NYSE: PFE) announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccin...

500,000 missed out on blood pressure lowering drug…

Nearly half a million people missed out on starting medication to lower their blood pressure during the COVID-19 pandemic, according to research supported by the British ...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Roche announces the European Commission approval o…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Commission (EC) has approved Xofluza® (baloxavir marboxil) in children aged one year and above for the trea...

Modified CRISPR-based enzymes improve the prospect…

Many genetic diseases are caused by diverse mutations spread across an entire gene, and designing genome editing approaches for each patient’s mutation would be impractic...

A soybean protein blocks LDL cholesterol productio…

A protein in soybeans blocks the production of a liver enzyme involved in the metabolism of triglycerides and low-density lipoprotein, scientists found in a recent study...

Discovery of anti-cancer chemistry makes skullcap …

The evolutionary secrets that enable the medicinal herb known as barbed skullcap to produce cancer fighting compounds have been unlocked by a collaboration of UK and Chin...